The Claim
In esophageal squamous cell carcinoma, low expression of hexokinase 3 (HK3) is associated with increased immune cell infiltration and improved survival, and HK3 deficiency synergizes with elevated creatine levels to promote M2 macrophage polarization and tumor progression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In esophageal squamous cell carcinoma, low levels of hexokinase 3 correlate with greater immune cell presence and longer survival, and when hexokinase 3 is deficient along with high creatine, M2 macrophage polarization increases and tumor progression accelerates.
See the scientific wording
In esophageal squamous cell carcinoma, low expression of hexokinase 3 (HK3) is associated with enhanced immune cell infiltration and improved survival, and its deficiency synergizes with high creatine to promote M2 macrophage polarization and tumor progression.
When hexokinase 3 is low and creatine is high, immune cells called macrophages switch from fighting cancer to helping it grow. This happens because the macrophages stop using sugar for energy and instead use creatine to produce a molecule that reduces harmful chemicals inside the cell. This change turns off signals that make macrophages attack tumors and turns on signals that make them suppress the immune system, allowing the tumor to grow unchecked.
What the research says
1 studyIn esophageal cancer, when the HK3 enzyme is low and creatine is high, the tumor tricks immune cells into helping it grow instead of fighting it, leading to worse outcomes. The study proves this combo makes tumors bigger and more dangerous.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.